BACKGROUND: Recent evidence suggests prostate cancer independent of treatment has atrophic effects on whole heart and left ventricular (LV) masses, associated with reduced endurance exercise capacity. In a pre-clinical model, we tested the hypothesis that high-intensity training could prevent cardiac atrophy with prostate cancer and alter cardiac protein degradation mechanisms. METHODS: Dunning R-3327 AT-1 prostate cancer cells (1×105) were injected into the ventral prostate lobe of 5-6 mo immunocompetent Copenhagen rats (n=24). These animals were randomized into two groups, tumor-bearing exercise (TBEX, n=15) or tumor bearing sedentary (TBS, n=9). Five days after surgery, TBEX animals began exercise on a treadmill (25 m/min, 15° incline) for 45-60 min/day for 18±2 days. Pre-surgery (Pre), and post-exercise training (Post) echocardiographic evaluation (Vivid S6, GE Health Care), using the parasternal short axis view, was used to examine ventricle dimensions. Markers of protein degradation (muscle atrophy F-box, Cathepsin B, Cathepsin L) in the left ventricle were semi-quantified via Western Blot. RESULTS: There were no significant differences in tumor mass between groups (TBEX 3.4±0.7, TBS 2.8±0.6 g, P=0.3), or body mass (TBEX 317±5, TBS 333±7 g, P=0.2). Heart-to-body mass ratio was lower in TBS group compared to TBEX (2.3±0.1 vs. 2.5±0.1 mg/g, P<0.05). LV/body mass ratio was also lower in the TBS group (1.6±0.1 vs. 1.8±0.1 mg/g, P<0.05). From Pre-Post, TBEX had significant increases in SV (~20% P<0.05) whereas TBS had no significant change. There were no significant differences between groups for markers of protein degradation. CONCLUSION: This study suggests that high-intensity exercise can improve LV function and increase LV mass concurrent with prostate cancer development, versus sedentary counterparts. Given cardiac dysfunction often manifests with conventional anti-cancer treatments, a short-term high-intensity training program, prior to treatment, may improve cardiac function and fatigue resistance in cancer patients. AJTR
BACKGROUND: Recent evidence suggests prostate cancer independent of treatment has atrophic effects on whole heart and left ventricular (LV) masses, associated with reduced endurance exercise capacity. In a pre-clinical model, we tested the hypothesis that high-intensity training could prevent cardiac atrophy with prostate cancer and alter cardiac protein degradation mechanisms. METHODS: Dunning R-3327 AT-1 prostate cancer cells (1×105) were injected into the ventral prostate lobe of 5-6 mo immunocompetent Copenhagen rats (n=24). These animals were randomized into two groups, tumor-bearing exercise (TBEX, n=15) or tumor bearing sedentary (TBS, n=9). Five days after surgery, TBEX animals began exercise on a treadmill (25 m/min, 15° incline) for 45-60 min/day for 18±2 days. Pre-surgery (Pre), and post-exercise training (Post) echocardiographic evaluation (Vivid S6, GE Health Care), using the parasternal short axis view, was used to examine ventricle dimensions. Markers of protein degradation (muscle atrophy F-box, Cathepsin B, Cathepsin L) in the left ventricle were semi-quantified via Western Blot. RESULTS: There were no significant differences in tumor mass between groups (TBEX 3.4±0.7, TBS 2.8±0.6 g, P=0.3), or body mass (TBEX 317±5, TBS 333±7 g, P=0.2). Heart-to-body mass ratio was lower in TBS group compared to TBEX (2.3±0.1 vs. 2.5±0.1 mg/g, P<0.05). LV/body mass ratio was also lower in the TBS group (1.6±0.1 vs. 1.8±0.1 mg/g, P<0.05). From Pre-Post, TBEX had significant increases in SV (~20% P<0.05) whereas TBS had no significant change. There were no significant differences between groups for markers of protein degradation. CONCLUSION: This study suggests that high-intensity exercise can improve LV function and increase LV mass concurrent with prostate cancer development, versus sedentary counterparts. Given cardiac dysfunction often manifests with conventional anti-cancer treatments, a short-term high-intensity training program, prior to treatment, may improve cardiac function and fatigue resistance in cancerpatients. AJTR
Authors: Lianne B Dolan; Karen Gelmon; Kerry S Courneya; John R Mackey; Roanne J Segal; Kirstin Lane; Robert D Reid; Donald C McKenzie Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-09-22 Impact factor: 4.254
Authors: Peter J Esau; Elizabeth M Gittemeier; Alexander B Opoku-Acheampong; Korynne S Rollins; Dryden R Baumfalk; David C Poole; Timothy I Musch; Bradley J Behnke; Steven W Copp Journal: Am J Cancer Res Date: 2017-12-01 Impact factor: 6.166
Authors: Viviane M Conraads; Nele Pattyn; Catherine De Maeyer; Paul J Beckers; Ellen Coeckelberghs; Véronique A Cornelissen; Johan Denollet; Geert Frederix; Kaatje Goetschalckx; Vicky Y Hoymans; Nadine Possemiers; Dirk Schepers; Bharati Shivalkar; Jens-Uwe Voigt; Emeline M Van Craenenbroeck; Luc Vanhees Journal: Int J Cardiol Date: 2014-10-25 Impact factor: 4.164
Authors: Lee W Jones; Benjamin L Viglianti; Jessica A Tashjian; Sejal M Kothadia; Stephen T Keir; Stephen J Freedland; Michael Q Potter; Eui Jung Moon; Thies Schroeder; James E Herndon; Mark W Dewhirst Journal: J Appl Physiol (1985) Date: 2009-12-03
Authors: Roanne J Segal; Robert D Reid; Kerry S Courneya; Ronald J Sigal; Glen P Kenny; Denis G Prud'Homme; Shawn C Malone; George A Wells; Chris G Scott; Monika E Slovinec D'Angelo Journal: J Clin Oncol Date: 2008-12-08 Impact factor: 44.544
Authors: Amanda L Hannan; Wayne Hing; Vini Simas; Mike Climstein; Jeff S Coombes; Rohan Jayasinghe; Joshua Byrnes; James Furness Journal: Open Access J Sports Med Date: 2018-01-26
Authors: Alec L E Butenas; Korynne S Rollins; Auni C Williams; Shannon K Parr; Stephen T Hammond; Carl J Ade; K Sue Hageman; Timothy I Musch; Steven W Copp Journal: Physiol Rep Date: 2021-09